Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272856 · ClinicalTrials.gov registry record · Phase 1
Study on the Safety of Abatacept in Relapsing Polychondritis
A Phase 1 study of Relapsing Polychondritis, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT01272856: Completed Phase 1 study of Relapsing Polychondritis, sponsored by Benaroya Research Institute.
NCT01272856 is a Phase 1 study of Relapsing Polychondritis that has completed, run by Benaroya Research Institute. The registered enrollment target is 4 participants, below the 1,373-participant average among 3 other Relapsing Polychondritis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01272856, a Phase 1 study of Relapsing Polychondritis, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of the study drug abatacept and see what effects (good and bad) it has in patients with relapsing polychondritis.
Conditions Studied
Interventions
- DRUG Abatacept
Study Locations (1)
Washington
- Virginia Mason Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
What the finished NCT01272856 record still lists
NCT01272856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,373-participant average among 3 other Relapsing Polychondritis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Relapsing Polychondritis appearing as the primary indexed condition, and to 1 intervention - of which Abatacept is the first listed.
NCT01272856 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01272856 about?
NCT01272856 is a clinical study titled "Study on the Safety of Abatacept in Relapsing Polychondritis". The purpose of this study is to test the safety of the study drug abatacept and see what effects (good and bad) it has in patients with relapsing polychondritis.
What is the current status of trial NCT01272856?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-01. Estimated completion is 2012-05.
What conditions does trial NCT01272856 study?
This clinical trial studies the following conditions: Relapsing Polychondritis.
What interventions are being tested in trial NCT01272856?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT01272856?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01272856 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Polychondritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia